Takayasu's arteritis medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Takayasu's arteritis}} | {{Takayasu's arteritis}} | ||
{{CMG}} {{AE}} {{FKH}} | {{CMG}} {{AE}} {{FKH}} | ||
| Line 8: | Line 7: | ||
==Overview== | ==Overview== | ||
==Medical Therapy== | ==Medical Therapy== | ||
Medical therapy of Takayasu arteritis depends on the disease activity and the complications that develop. | |||
The two most important aspects of treatment: | |||
* Controlling the inflammatory process | |||
* Controlling [[hypertension]] | |||
=== Corticosteroids === | |||
=== IL-6 receptor inhibitor === | |||
=== B-cell depletion === | |||
=== Cytotoxic agents === | |||
=== Anti-tumor necrosis factor agents === | |||
==References== | ==References== | ||
Revision as of 19:24, 11 April 2018
|
Takayasu's arteritis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Takayasu's arteritis medical therapy On the Web |
|
American Roentgen Ray Society Images of Takayasu's arteritis medical therapy |
|
Risk calculators and risk factors for Takayasu's arteritis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Farnaz Khalighinejad, MD [2]
Overview
Medical Therapy
Medical therapy of Takayasu arteritis depends on the disease activity and the complications that develop.
The two most important aspects of treatment:
- Controlling the inflammatory process
- Controlling hypertension